Vanguard Group Inc. Boosts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Vanguard Group Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,158,926 shares of the medical research company's stock after acquiring an additional 60,497 shares during the period. Vanguard Group Inc. owned approximately 12.04% of Charles River Laboratories International worth $1,136,938,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRL. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. raised its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. Tortoise Investment Management LLC lifted its position in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International in the third quarter worth approximately $59,000. Finally, ORG Wealth Partners LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $56,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In other news, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Barclays cut their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 18th. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a report on Monday, March 3rd. Finally, Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $189.77.

Charles River Laboratories International Trading Down 0.1 %

NYSE:CRL traded down $0.12 during trading hours on Wednesday, hitting $145.87. The company had a trading volume of 200,098 shares, compared to its average volume of 760,352. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a 50-day moving average price of $163.95 and a 200 day moving average price of $181.92. The company has a market capitalization of $7.46 billion, a PE ratio of 969.98, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 52 week low of $143.33 and a 52 week high of $267.83.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the firm posted $2.46 EPS. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).